2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
2006
Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial
Mohamed S, Osatuke K, Aslam M, Kasckow J. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial. The American Journal Of Geriatric Pharmacotherapy 2006, 4: 201-209. PMID: 17062320, DOI: 10.1016/j.amjopharm.2006.08.001.Peer-Reviewed Original ResearchConceptsMajor depressive disorderComorbid major depressive disorderElderly patientsComorbid depressionEscitalopram 10Adverse eventsPilot trialBaseline Montgomery-Asberg Depression Rating Scale (MADRS) scoreMontgomery-Asberg Depression Rating Scale scoreSecondary efficacy end pointsSelective serotonin reuptake inhibitorsDepression Rating Scale scoresVeterans Affairs Medical CenterEfficacy end pointPrimary efficacy variableMedical Outcomes StudySerotonin reuptake inhibitorsShort-term administrationHAM-A scoresHamilton Rating ScaleLack of efficacyPoor treatment responseRating Scale scoresSymptoms of depressionGreater symptom severity